The prognostic significance of miR-150, GAB1, or FOXP1 in a univariate analysis
| . | Univariate Cox regression model of OS . | Univariate Cox regression model of TFS . | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| n = 154, number of events = 39* . | n = 107, number of events = 58* . | ||||||||||||
| Nondelayed entry model . | Delayed entry model . | Nondelayed entry model . | Delayed entry model . | ||||||||||
| Variable . | HR . | CI . | P . | HR . | CI . | P . | HR . | CI . | P . | HR . | CI . | P . | |
| miR-150 (≤ vs > median) | 2.8 | 1.3-5.9 | .01 | 3.2 | 1.5-6.7 | .003 | 1.7 | 1-2.8 | .057 | 2.3 | 1.4-4 | .002 | |
| GAB1 (> vs ≤ median) | 2.3 | 1.2-4.4 | .02 | 1.7 | 0.9-3.3 | .12 | 2.1 | 1.3-3.6 | .005 | 2.4 | 1.4-4.1 | .002 | |
| FOXP1 (> vs ≤ median) | 2.4 | 1.2-4.8 | .02 | 2.9 | 1.4-5.8 | .004 | 1.4 | 0.8-2.3 | .3 | 1.3 | 0.7-2.1 | .39 | |
| IGHV (unmut. vs mut.) | 12.2 | 4.9-30.5 | <.001 | 7.5 | 3-18.9 | <.001 | 2.9 | 2-4.4 | <.001 | 2.5 | 1.4-4.2 | .001 | |
| ZAP-70 (pos. vs neg.) | 7.3 | 3.5-15.2 | <.001 | 7.7 | 3.3-18 | <.001 | 2.4 | 1.6-3.5 | <.001 | 2.3 | 1.3-3.9 | .002 | |
| CD38 (pos. vs neg.) | 3.0 | 1.6-5.7 | .001 | 2.7 | 1.4-5.2 | .003 | 2.5 | 1.7-3.8 | <.001 | 2.6 | 1.4-4.6 | .002 | |
| Gender (male vs female) | 1.3 | 0.7-2.5 | .5 | 1.2 | 0.6-2.4 | .56 | 1.4 | 1-2.2 | .08 | 1.4 | 0.8-2.5 | .2 | |
| Rai stage | I vs 0 | 2.9 | 0.9-9.2 | .07 | 2.3 | 0.7-7.5 | .16 | 1.4 | 0.8-2.4 | .2 | 0.8 | 0.4-1.7 | .63 |
| II vs 0 | 4.4 | 1.2-15.7 | .02 | 2.5 | 0.7-9.1 | .15 | 3.2 | 1.8-5.8 | <.001 | 1.2 | 0.5-2.6 | .66 | |
| ≥III vs 0 | 12.0 | 3.5-40.9 | <.001 | 7.1 | 2.1-24 | .002 | 5.2 | 2.4-11.1 | <.001 | 3.2 | 0.7-14.4 | .13 | |
| Age (> vs ≤ median) | 3.3 | 1.7-6.6 | <.001 | 2.7 | 1.3-5.7 | .008 | 1.1 | 0.7-1.6 | .75 | 0.9 | 0.5-1.6 | .76 | |
| del17p13 | 2.9 | 1-8.8 | .06 | 3.3 | 1.1-10 | .04 | 1.9 | 1-3.8 | .05 | 2.4 | 1-5.8 | .05 | |
| dell11q23 | 2.6 | 0.9-8 | .09 | 1.6 | 0.5-4.8 | .43 | 2.4 | 1.3-4.4 | .007 | 1.8 | 0.8-4 | .13 | |
| . | Univariate Cox regression model of OS . | Univariate Cox regression model of TFS . | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| n = 154, number of events = 39* . | n = 107, number of events = 58* . | ||||||||||||
| Nondelayed entry model . | Delayed entry model . | Nondelayed entry model . | Delayed entry model . | ||||||||||
| Variable . | HR . | CI . | P . | HR . | CI . | P . | HR . | CI . | P . | HR . | CI . | P . | |
| miR-150 (≤ vs > median) | 2.8 | 1.3-5.9 | .01 | 3.2 | 1.5-6.7 | .003 | 1.7 | 1-2.8 | .057 | 2.3 | 1.4-4 | .002 | |
| GAB1 (> vs ≤ median) | 2.3 | 1.2-4.4 | .02 | 1.7 | 0.9-3.3 | .12 | 2.1 | 1.3-3.6 | .005 | 2.4 | 1.4-4.1 | .002 | |
| FOXP1 (> vs ≤ median) | 2.4 | 1.2-4.8 | .02 | 2.9 | 1.4-5.8 | .004 | 1.4 | 0.8-2.3 | .3 | 1.3 | 0.7-2.1 | .39 | |
| IGHV (unmut. vs mut.) | 12.2 | 4.9-30.5 | <.001 | 7.5 | 3-18.9 | <.001 | 2.9 | 2-4.4 | <.001 | 2.5 | 1.4-4.2 | .001 | |
| ZAP-70 (pos. vs neg.) | 7.3 | 3.5-15.2 | <.001 | 7.7 | 3.3-18 | <.001 | 2.4 | 1.6-3.5 | <.001 | 2.3 | 1.3-3.9 | .002 | |
| CD38 (pos. vs neg.) | 3.0 | 1.6-5.7 | .001 | 2.7 | 1.4-5.2 | .003 | 2.5 | 1.7-3.8 | <.001 | 2.6 | 1.4-4.6 | .002 | |
| Gender (male vs female) | 1.3 | 0.7-2.5 | .5 | 1.2 | 0.6-2.4 | .56 | 1.4 | 1-2.2 | .08 | 1.4 | 0.8-2.5 | .2 | |
| Rai stage | I vs 0 | 2.9 | 0.9-9.2 | .07 | 2.3 | 0.7-7.5 | .16 | 1.4 | 0.8-2.4 | .2 | 0.8 | 0.4-1.7 | .63 |
| II vs 0 | 4.4 | 1.2-15.7 | .02 | 2.5 | 0.7-9.1 | .15 | 3.2 | 1.8-5.8 | <.001 | 1.2 | 0.5-2.6 | .66 | |
| ≥III vs 0 | 12.0 | 3.5-40.9 | <.001 | 7.1 | 2.1-24 | .002 | 5.2 | 2.4-11.1 | <.001 | 3.2 | 0.7-14.4 | .13 | |
| Age (> vs ≤ median) | 3.3 | 1.7-6.6 | <.001 | 2.7 | 1.3-5.7 | .008 | 1.1 | 0.7-1.6 | .75 | 0.9 | 0.5-1.6 | .76 | |
| del17p13 | 2.9 | 1-8.8 | .06 | 3.3 | 1.1-10 | .04 | 1.9 | 1-3.8 | .05 | 2.4 | 1-5.8 | .05 | |
| dell11q23 | 2.6 | 0.9-8 | .09 | 1.6 | 0.5-4.8 | .43 | 2.4 | 1.3-4.4 | .007 | 1.8 | 0.8-4 | .13 | |
CI, confidence interval (of 95%); HR, hazard ratio. The values in rows miR-150, GAB1, and FOXP1 are boldfaced to highlight results for these genes of interest.
Analysis for miR-150, GAB1, and FOXP1 includes only samples obtained before the last day of follow-up for OS analysis (154/168) or before first therapy for TFS analysis (107/168); the others use all available samples.